Scisparc Ltd (SPRC)

$6.74 -0.42 (-5.87%)
Market Cap 4.03M
Revenue (ttm) 860,000.00
Net Income (ttm) -12.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,416.28%
Debt to Equity Ratio 0.07
Volume 17,031
Avg Vol 1,129,680
Day's Range N/A - N/A
Shares Out 566,000.00
Stochastic %K 37%
Beta 2.79
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially man...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv-Yafo, Israel
ExploringTrades
ExploringTrades Aug. 4 at 7:14 PM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $SPRC $OBAI dkd{
0 · Reply
BreakoutTrends
BreakoutTrends Aug. 4 at 5:15 PM
$SPRC lane
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 3 at 9:59 PM
$SPRC watchlist39
0 · Reply
Barryman1
Barryman1 Aug. 3 at 3:43 PM
$XAIR Higher highs Higher lows 😁 Just like my $SPRC and $CYCU calls last week Interesting…
0 · Reply
MovingFast77
MovingFast77 Aug. 3 at 1:42 PM
$GPRO $CIGL $SMX $SPRC
1 · Reply
MovingFast77
MovingFast77 Aug. 1 at 12:27 PM
$GPRO $CIGL $SMX did you get some $SPRC
1 · Reply
Barryman1
Barryman1 Jul. 31 at 6:13 PM
$SCYX market starts to realize below 👇 Other great calls this week: $SPRC and $CYCU
0 · Reply
Barryman1
Barryman1 Jul. 31 at 4:11 PM
$FFAI it keeps being strong Reminds me on $SPRC and $CYCU earlier this week📈
1 · Reply
pennysqueezepro
pennysqueezepro Jul. 31 at 3:28 PM
$FFAI $GWAV $SPRC THERE YOU GO FOLLOWERS!!!👀
1 · Reply
pennysqueezepro
pennysqueezepro Jul. 31 at 3:06 PM
$FFAI $GWAV $SPRC TOLD YOU FOLLOWERS!!! FOLLOW ME IF YOU WANT $FFAI HALT UP $SHPH DUE FOR BOUNCE 
1 · Reply
Latest News on SPRC
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

Jul 31, 2026, 8:20 AM EDT - 4 days ago

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

Scisparc Ltd trading resumes

2026-07-29T14:00:47.000Z - 6 days ago

Scisparc Ltd trading resumes

Scisparc Ltd trading halted, volatility trading pause

2026-07-29T13:56:02.000Z - 6 days ago

Scisparc Ltd trading halted, volatility trading pause

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

Jul 29, 2026, 8:32 AM EDT - 6 days ago

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

SciSparc to target agentic artificial intelligence market

2026-07-27T13:16:01.000Z - 8 days ago

SciSparc to target agentic artificial intelligence market

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Jul 27, 2026, 8:25 AM EDT - 8 days ago

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

SciSparc initiates SCI-110 clinical trial in Germany

2026-07-15T13:06:01.000Z - 20 days ago

SciSparc initiates SCI-110 clinical trial in Germany

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Jul 15, 2026, 8:41 AM EDT - 20 days ago

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Jul 15, 2026, 8:31 AM EDT - 20 days ago

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TS

NeuroThera Labs Announces Upsize to Private Placement

Jul 2, 2026, 5:30 PM EDT - 4 weeks ago

NeuroThera Labs Announces Upsize to Private Placement

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

Jun 30, 2026, 6:00 PM EDT - 4 weeks ago

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

Jun 4, 2026, 7:32 AM EDT - 2 months ago

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

Jun 3, 2026, 5:15 PM EDT - 2 months ago

Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

May 28, 2026, 8:40 AM EDT - 2 months ago

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

Neurothera Labs Announces Adoption of Semi-Annual Reporting

May 20, 2026, 5:00 PM EDT - 2 months ago

Neurothera Labs Announces Adoption of Semi-Annual Reporting

Neurothera Labs Announces Continuance into Ontario

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Neurothera Labs Announces Continuance into Ontario

Neurothera Labs Engages bullVestor for Investor Relations Activities

Apr 23, 2026, 6:00 PM EDT - 3 months ago

Neurothera Labs Engages bullVestor for Investor Relations Activities

SciSparc discloses patent application for depression yherapy

2026-03-16T12:25:23.000Z - 5 months ago

SciSparc discloses patent application for depression yherapy

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Mar 16, 2026, 8:20 AM EDT - 5 months ago

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc’s Neurothera Labs announces publication of international patent

2026-03-12T12:01:25.000Z - 5 months ago

SciSparc’s Neurothera Labs announces publication of international patent

CMND

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 12, 2026, 7:55 AM EDT - 5 months ago

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

2026-03-10T13:38:10.000Z - 5 months ago

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Mar 10, 2026, 9:28 AM EDT - 5 months ago

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

CMND

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Scisparc Ltd trading halted, news pending

2026-03-04T00:50:09.000Z - 5 months ago

Scisparc Ltd trading halted, news pending

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:35:06.000Z - 5 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:28:37.000Z - 5 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:23:28.000Z - 5 months ago

SciSparc announces 1-for-9 reverse share split

SciSparc Announces 1-for-9 Reverse Share Split

Mar 2, 2026, 8:00 AM EST - 5 months ago

SciSparc Announces 1-for-9 Reverse Share Split

SciSparc files to sell 23.04M ordinary shares for holders

2026-02-17T22:30:16.000Z - 5 months ago

SciSparc files to sell 23.04M ordinary shares for holders

SciSparc files $50M mixed securities shelf

2026-02-03T21:40:29.000Z - 6 months ago

SciSparc files $50M mixed securities shelf

SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech

2026-02-02T13:36:11.000Z - 6 months ago

SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:24 AM EST - 6 months ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 6 months ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc completes acquisition of IP portfolio of patents, trademarks

2026-01-26T13:20:59.000Z - 6 months ago

SciSparc completes acquisition of IP portfolio of patents, trademarks

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Jan 26, 2026, 8:13 AM EST - 6 months ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc to acquire a treasury of patents for the endoscope market

2026-01-13T12:00:18.000Z - 7 months ago

SciSparc to acquire a treasury of patents for the endoscope market

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

Jan 13, 2026, 6:55 AM EST - 7 months ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc receives noncompliance notification from Nasdaq

2026-01-12T21:11:27.000Z - 7 months ago

SciSparc receives noncompliance notification from Nasdaq

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 12, 2026, 4:02 PM EST - 7 months ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

Jan 8, 2026, 6:00 PM EST - 7 months ago

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:17 AM EST - 7 months ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 7 months ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 9:29 AM EST - 8 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 8 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Dec 1, 2025, 8:32 AM EST - 8 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 26, 2025, 7:38 AM EST - 8 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 20, 2025, 6:42 AM EST - 9 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 9 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 10 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 10 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 10 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 10 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 10 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 10 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 10 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 11 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 11 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 1 year ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 1 year ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 1 year ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 1 year ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 1 year ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 1 year ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 1 year ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 1 year ago

SciSparc Announces Publication of Japanese Patent Application

ExploringTrades
ExploringTrades Aug. 4 at 7:14 PM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $SPRC $OBAI dkd{
0 · Reply
BreakoutTrends
BreakoutTrends Aug. 4 at 5:15 PM
$SPRC lane
0 · Reply
TwinTurboBul161
TwinTurboBul161 Aug. 3 at 9:59 PM
$SPRC watchlist39
0 · Reply
Barryman1
Barryman1 Aug. 3 at 3:43 PM
$XAIR Higher highs Higher lows 😁 Just like my $SPRC and $CYCU calls last week Interesting…
0 · Reply
MovingFast77
MovingFast77 Aug. 3 at 1:42 PM
$GPRO $CIGL $SMX $SPRC
1 · Reply
MovingFast77
MovingFast77 Aug. 1 at 12:27 PM
$GPRO $CIGL $SMX did you get some $SPRC
1 · Reply
Barryman1
Barryman1 Jul. 31 at 6:13 PM
$SCYX market starts to realize below 👇 Other great calls this week: $SPRC and $CYCU
0 · Reply
Barryman1
Barryman1 Jul. 31 at 4:11 PM
$FFAI it keeps being strong Reminds me on $SPRC and $CYCU earlier this week📈
1 · Reply
pennysqueezepro
pennysqueezepro Jul. 31 at 3:28 PM
$FFAI $GWAV $SPRC THERE YOU GO FOLLOWERS!!!👀
1 · Reply
pennysqueezepro
pennysqueezepro Jul. 31 at 3:06 PM
$FFAI $GWAV $SPRC TOLD YOU FOLLOWERS!!! FOLLOW ME IF YOU WANT $FFAI HALT UP $SHPH DUE FOR BOUNCE 
1 · Reply
Stef_Gee
Stef_Gee Jul. 31 at 2:15 PM
$SPRC 🥱
0 · Reply
DrUser
DrUser Jul. 31 at 2:12 PM
$SPRC
0 · Reply
Stef_Gee
Stef_Gee Jul. 31 at 1:49 PM
$SPRC The most important sentence is buried in the middle : "The workflow was executed within a quantum simulation environment", so they did not run this on quantum hardware, they demonstrated that their software pipeline could ingest clinical data, process it through simulated quantum "style" methods and produce interpretable output
2 · Reply
focafoca99
focafoca99 Jul. 31 at 1:45 PM
$SPRC demonstrates its NeuroThera Labs quantum platform delivering a full hybrid quantum-classical workflow for clinical data analytics.
0 · Reply
Stef_Gee
Stef_Gee Jul. 31 at 1:12 PM
$SPRC 😏
1 · Reply
MasterOfMyDomains
MasterOfMyDomains Jul. 31 at 1:09 PM
$SPRC What happened to DFNS 2.0?
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 31 at 12:20 PM
$SPRC SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
0 · Reply
TwinTurboBul161
TwinTurboBul161 Jul. 30 at 8:32 PM
$RACC $SPRC watching3
0 · Reply
Barryman1
Barryman1 Jul. 30 at 8:26 PM
$CTM it s coming - Be early $CYCU 😁🤑🤑 $SPRC holding
1 · Reply
Stef_Gee
Stef_Gee Jul. 30 at 7:00 PM
$SPRC Another long upper wick on the daily chart, with only 683K volume, I’ve seen this movie many times before an after hours offering announcement😏
1 · Reply